Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.

ABSTRACT:

Background

Invasive (IPD, defined as detection of pneumococci in sterile body fluids like meningitis or bacteremic pneumonia) and non-invasive Streptococcus pneumoniae infections (i.e. non-bacteremic pneumonia, otitis media) in adults are associated with substantial morbidity, mortality and costs. In Germany, Pneumococcal polysaccharide vaccination (PPV23) is recommended for all persons >60 years and for defined risk groups (age 5-59). The aim of this model was to estimate the potential cost-effectiveness and benefit-cost ratios of the adult vaccination program (18 years and older), considering the launch of the pneumococcal conjugate vaccine for adults (PCV13).

Methods

A cross-sectional steady state Markov model was developed to estimate the outcomes of PCV13, PPV23 vaccina

SUBMITTER: Kuhlmann A 

PROVIDER: S-EPMC3463422 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature